Navigation Links
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Date:1/20/2010

re weak inhibitors of the liver enzyme CYP2D6.  The weak inhibitors of the enzyme include Celexa® (citalopram), Lexapro® (escitalopram), and Luvox® (fluvoxamine).
  • Evidence indicates that physicians have adjusted prescribing habits after the FDA published alerts and inserted boxed warnings into product labels for Erythropoiesis Stimulating Agents (ESAs) in 2007.  This resulted in a reduction in the spend for these agents.  Additional studies are planned to determine if this decrease led to any change in ER visits or hospitalizations for this group of patients.
  • Assessment of patients with chronic myeloid leukemia should include testing for the BCR-ABL gene and its product.  Physicians are not conducting necessary follow-up gene testing for Gleevec patients to determine whether the treatment is working.  Only 14 percent of patients had the BCR-ABL gene measured for consecutive quarters.  Only 60 percent had evidence of having one gene test performed at any period over 1.5 years.

  • For more information about Medco's research, please visit www.medcoresearch.com.

    About Medco

    Medco Health Solutions, Inc. (NYSE: MHS) is pioneering the world's most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter™ for more than 60 million members.

    With more than 20,000 employees dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2008 revenue exceeding

    SOURCE Medco Health Solutions, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Medco to Present at Upcoming Investor Conferences
    2. Medco Partners with AmeriCares to Rush Donated Medicines to Help Victims of the Haiti Earthquake
    3. Medco, State of Illinois and Community Retail Pharmacies Launch Wired Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs
    4. Medco Reforming Healthcare with Smarter Medicine; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost
    5. Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75
    6. Medco to Present at November 2009 Investor Conferences
    7. The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need
    8. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
    9. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
    10. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
    11. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
    (Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
    (Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
    Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
    ... SAN DIEGO, Aug. 26 CareFusion (NYSE: ... announced the national commercial launch of the AVA max® ... during kyphoplasty, a procedure for treating spinal compression fractures. ... represents a competitive breakthrough and is expected to enhance ...
    ... Inc. (Nasdaq: ALXA ) announced today that ... to Cypress Bioscience, Inc. (Nasdaq: CYPB).  The Staccato ... system designed to help people stop smoking.  The ... a well-validated smoking cessation approach by delivering nicotine via ...
    Cached Medicine Technology:CareFusion Announces National Launch of Spinal Fracture Device 2CareFusion Announces National Launch of Spinal Fracture Device 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 2Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 4
    (Date:7/11/2014)... 11, 2014 The Europe Well Intervention Market ... Europe with analysis and revenue forecast. The well intervention services ... billion in 2013 to $3.4 billion by 2018, at a ... the TOC of the Europe Well Intervention Market report, to ... provides a glimpse of the segmentation in the Europe well ...
    (Date:7/11/2014)... 2014 Operators and owners ... in fuel costs now that model 2019 ... GHG standards are phasing in 2014-2018 ... themselves to install new features into their ... technologies , 2.    Efficient driveline components which reduce ...
    (Date:7/11/2014)... July 11, 2014 (HealthDay News) -- U.S. health officials ... were exposed to live anthrax during a safety mishap ... Control and Prevention officials have announced a moratorium on ... high-level government labs. In a report issued Friday, ... to make sure a similar incident doesn,t occur again. ...
    (Date:7/11/2014)... (PRWEB) July 11, 2014 Alliance ... nation’s only non-profit dedicated exclusively to cell and ... Joshua Corday has joined the organization as Senior ... professional with deep experience securing gifts and addressing ... as Annual Giving Director for NewYork Presbyterian Hospital/Columbia ...
    (Date:7/11/2014)... are widely applied in turf and ornamentals. They enhance ... turf and ornamentals in absorption of water, nutrient uptake, ... appear healthy and strong as a result of using ... few years. The most dominating region in biostimulants markets ... share in 2013, and is estimated to grow at ...
    Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
    ... AstraZeneca and the Drugs for Neglected Diseases initiative ... drug-compound screening for leishmaniasis, Chagas disease, and sleeping ... affect nearly 10 million people worldwide. Novel drug ... the drug development pipeline for new medicines urgently ...
    ... April 11, 2012 -- In a scientific paper published ... from SomaLogic and the University of Washington in Seattle ... technology to tissue samples. Working with both tumor and ... cancer (NSCLC), they identified significant expression changes in 36 ...
    ... 11 (HealthDay News) -- Holding a gun makes a man appear ... Researchers at the University of California, Los Angeles, asked hundreds ... simply by looking at photos of the men,s hands holding a ... a large saw or a handgun. The hands of the ...
    ... November 2011, a National Academy of Sciences committee issued ... Maps"-like data network intended to revolutionize medical discovery, diagnosis ... Chancellor Susan Desmond-Hellmann, MD, MPH, is issuing a call-to-arms ... reality. In her editorial, reported in the April ...
    ... rapidly as California,s population ages, but the majority of state,s ... access to health care and food, a new study from ... Fifty-seven percent of paid Medi-Cal caregivers and ... have incomes that leave them in poverty or near ...
    ... Denise Mann HealthDay Reporter , WEDNESDAY, April 11 ... disability after a stroke, but they must be given within ... too late to use them. Now, German researchers report ... problem: mobile stroke units. Equipped with what is needed to ...
    Cached Medicine News:Health News:AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases 2Health News:SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples 2Health News:People Carrying Guns May Appear Bigger Than They Are 2Health News:UCSF chancellor issues call-to-arms to patient advocates 2Health News:UCSF chancellor issues call-to-arms to patient advocates 3Health News:Majority of California's Medi-Cal caregivers live in or near poverty 2Health News:Majority of California's Medi-Cal caregivers live in or near poverty 3Health News:Mobile Stroke Units Might Trim Time to Treatment 2
    The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
    Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
    ... is the most versatile orthopedic/trauma ... designed for both lower body ... an integrated shoulder attachment. The ... operating table for your most ...
    ... With MARS, the operating theatre is ready for ... surgical fields. Its modern design allows a quick, ... The individual components are connected securely and sturdily ... system. And if there should ever be a ...
    Medicine Products: